These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23307546)

  • 1. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
    Davis KL; Tangirala M; Meyers JL; Wei W
    Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM
    Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
    Wallace JP; Wallace JL; McFarland MS
    Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
    Galindo RJ; Davis GM; Fayfman M; Reyes-Umpierrez D; Alfa D; Peng L; Tamler R; Pasquel FJ; Umpierrez GE
    Endocr Pract; 2017 Sep; 23(9):1059-1066. PubMed ID: 28683239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
    Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
    J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of insulin detemir in Japanese children with type 1 diabetes.
    Jinno K; Urakami T; Horikawa R; Kawamura T; Kikuchi N; Kikuchi T; Kizu R; Kosaka K; Mizuno H; Mochizuki T; Nishii A; Ohki Y; Soneda S; Sugihara S; Tatematsu T; Amemiya S;
    Pediatr Int; 2012 Dec; 54(6):773-9. PubMed ID: 22726205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome.
    Callesen NF; Damm J; Mathiesen JM; Ringholm L; Damm P; Mathiesen ER
    J Matern Fetal Neonatal Med; 2013 Apr; 26(6):588-92. PubMed ID: 23211128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.